Table 1.
Feature | miR-196-5p | P value | |
---|---|---|---|
High | Low | ||
Age, year | 0.437 | ||
≥55 | 59 | 65 | |
<55 | 34 | 28 | |
Gender | 0.282 | ||
Male | 78 | 83 | |
Female | 15 | 10 | |
HBsAg | 0.809 | ||
Positive | 84 | 83 | |
Negative | 9 | 10 | |
HBeAg | 0.216 | ||
Positive | 69 | 76 | |
Negative | 24 | 17 | |
AFP, μg/L | 0.028 | ||
≥20 | 63 | 76 | |
<20 | 30 | 17 | |
Tumor size, cm | 0.037 | ||
≥5 | 48 | 62 | |
<5 | 45 | 31 | |
Tumor number | < 0.001 | ||
Single | 86 | 60 | |
Multiple | 7 | 33 | |
Vascular invasion | 0.036 | ||
Present | 49 | 63 | |
Absent | 44 | 30 | |
Hepatitis B virus DNA,IU/mL | 0.237 | ||
≥1.0°× 103 | 45 | 37 | |
<1.0°× 103 | 48 | 56 | |
Tumor differentiation | 0.226 | ||
I–II | 7 | 12 | |
III–IV | 86 | 81 | |
TNM tumor stage | < 0.001 | ||
I–II | 86 | 67 | |
III–IV | 7 | 26 |
The median miR-196-5p expression level served as the cut-off value to differentiate high and low-expression groups (those above and below the 50th percentile, respectively; n = 93 each). The correlation between miR-196-5p expression and patient clinical features was assessed via chi-squared tests. P < 0.05 was the significance threshold